We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-11.11%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
-$1.54B
Cap. Flow
-$210M
Cap. Flow %
-2.97%
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$67.9M
2
PFE icon
Pfizer
PFE
+$40.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.9M
4
HRMY icon
Harmony Biosciences
HRMY
+$26M
5
CRL icon
Charles River Laboratories
CRL
+$25.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$100M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.4M
3
ABBV icon
AbbVie
ABBV
+$47.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.26%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
126
Arcus Biosciences
RCUS
$3.74B
$2.28M 0.03%
90,100
-21,600
-19% -$529K
SNY icon
127
Sanofi
SNY
$104B
$2.12M 0.03%
42,300
-1,300
-3% -$69K
KOS icon
128
Kosmos Energy
KOS
$1.63B
$1.97M 0.03%
318,300
-93,700
-23% -$676K
BMY icon
129
Bristol-Myers Squibb
BMY
$126B
$1.92M 0.03%
24,907
-603,221
-96% -$45.9M
CELL
130
DELISTED
PhenomeX Inc. Common Stock
CELL
$1.91M 0.03%
385,014
– –
RARE icon
131
Ultragenyx Pharmaceutical
RARE
$2.66B
$1.85M 0.03%
31,000
+5,300
+21% +$326K
COR icon
132
Cencora
COR
$59.4B
$1.84M 0.03%
13,000
– –
NVCR icon
133
NovoCure
NVCR
$2.32B
$1.76M 0.02%
25,300
+16,800
+198% +$1.27M
BCYC
134
Bicycle Therapeutics
BCYC
$290M
$1.42M 0.02%
84,400
+47,900
+131% +$1.01M
SEER icon
135
Seer Inc
SEER
$113M
$1.22M 0.02%
136,133
– –
KURA icon
136
Kura Oncology
KURA
$928M
$1.17M 0.02%
63,700
-2,280
-3% -$32.8K
LH icon
137
Labcorp
LH
$23.9B
$996K 0.01%
4,947
– –
KRYS icon
138
Krystal Biotech
KRYS
$9.65B
$880K 0.01%
13,400
-400
-3% -$24.9K
INBX
139
DELISTED
Inhibrx, Inc. Common Stock
INBX
$869K 0.01%
76,600
+26,900
+54% +$396K
MCK icon
140
McKesson
MCK
$96.5B
$828K 0.01%
2,537
+263
+12% +$84.1K
NTLA icon
141
Intellia Therapeutics
NTLA
$1.55B
$817K 0.01%
15,794
-500
-3% -$25.4K
XNCR icon
142
Xencor
XNCR
$1.45B
$725K 0.01%
26,500
-15,100
-36% -$372K
RDY icon
143
Dr. Reddy's Laboratories
RDY
$9.83B
$687K 0.01%
62,000
+19,500
+46% +$212K
RLMD icon
144
Relmada Therapeutics
RLMD
$546M
$665K 0.01%
35,000
+19,000
+119% +$414K
GOOG icon
145
Alphabet (Google) Class C
GOOG
$3.89T
$656K 0.01%
6,000
+3,300
+122% +$390K
ARCT icon
146
Arcturus Therapeutics
ARCT
$165M
$623K 0.01%
39,550
-1,350
-3% -$26.5K
VRDN icon
147
Viridian Therapeutics
VRDN
$2.13B
$567K 0.01%
+49,000
New +$659K
CRBU icon
148
Caribou Biosciences
CRBU
$162M
$382K 0.01%
+70,300
New +$537K
GDX icon
149
VanEck Gold Miners ETF
GDX
$22.9B
$367K 0.01%
13,400
– –
SLN
150
Silence Therapeutics
SLN
$541M
$361K 0.01%
30,483
-16,183
-35% -$197K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2022 Portfolio in Review

As of Q2 2022, Bellevue Group held 187 positions worth $7.07B, down 18% from $8.61B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q2 2022 filing shows 10 new, 57 increased, 82 reduced and 15 closed positions. Its largest new stake was Celldex Therapeutics: 925,000 shares worth $24.9M. The largest sale was Elevance Health, an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2022 buy was Celldex Therapeutics: 925,000 shares worth $24.9M.
  • Bellevue Group added most to Intuitive Surgical in Q2 2022, an estimated $67.9M increase.
  • Bellevue Group's biggest Q2 2022 reduction was Elevance Health, cutting an estimated $100M.
  • Bellevue Group fully exited Dentsply Sirona in Q2 2022, selling an estimated $7.83M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.07B portfolio in Q2 2022.
  • Bellevue Group opened 10 new positions and closed 15 in Q2 2022.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.